The members of the Network of Pathologists in Brittany are listed in Appendix 1.
Introduction
Given the high prevalence of prostate cancer [1] and the risks of morbidity from treatment [2] or from active surveillance with follow-up biopsies [3] , the primary prevention of prostate cancer is of great importance. Two large randomized trials [4, 5] have shown that 5a-reductase inhibitors (5-ARIs) reduced overall prostate cancer risk by 20% to 25%, but they also showed a statistically significant increased risk of high grade cancer (Gleason score [7] [8] [9] [10] , and, to date, the use of 5-ARIs has not been recommended for primary prevention of the disease [6] [7] [8] .
The reason for the observed increased risk is unclear [9] , and study results have been subject to detection bias [10, 11] .
Treatment with 5-ARIs has clear benefits for men with LUTS related to BPH [12, 13] . In such men, no difference was observed regarding the number of Gleason score 8-10 cancers in those allocated to dutasteride compared with those allocated to tamsulosin [14] . Although three observational studies [15] [16] [17] reported somewhat reassuring results, their findings did not exclude an increased risk of high grade prostate cancer. Considering that the association between 5-ARI use and high grade prostate cancer is still debated, we conducted the 'CANARI' study to investigate the association between 5-ARI use and prostate cancer according to Gleason score (< 8 or ≥ 8) and compared the results with non-use of 5-ARIs.
Patients and Methods

Study Design, Setting and Patients
This population-based matched case-control study used data (2010-2013) from the comprehensive French national health insurance database (SNIIRAM), linked to data from all pathology laboratories located in Brittany, France.
The study design and linkage methodology have been described previously [18] . Among men living in Brittany, all treated for symptomatic or complicated BPH in 2010-2011 (Table S1) , we identified incident cases of prostate cancer in 2012-2013 (Table S2 ) and confirmed the diagnosis by linkage to pathology results (Gleason score). We then identified patients with high grade prostate cancer (Gleason score ≥8) and those with low grade prostate cancer (Gleason score < 8).
To be eligible, a case had to have a delay of at least 1 year between the first observed delivery of drug for BPH and prostate cancer diagnosis. The study flow is shown in Fig. 1 . For each case, five controls who were alive and free from prostate cancer at the date of diagnosis of the case (index date) were randomly selected from the cohort. They were matched on age and delay between the first observed drug delivery for BPH and index date using an incidence density sampling design.
Exposure
We defined 5-ARI users as patients with at least two drug deliveries. The remaining patients were categorized as '5-ARI non-users' (Table S1 ). Exposure was quantified by the cumulative duration of 5-ARIs dispensed, calculated from all data observed (backward from index date to 1 January 2010) and categorized for the sake of clarity into three classes (< 1 year, ≥ 1 year to < 2 years, ≥ 2 years).
Variables and Sources of Data
Using SNIIRAM data [19] , we classified cases and controls as having or not some prespecified comorbidities (Table S2) 
Study Size
At a 5% two-sided significance level, based on the hypothesis of a 5-ARI exposure frequency of 20% among controls [22] , 98 cases of high grade prostate cancer and 490 controls (1:5 case-to-control ratio) would allow the detection of an odds ratio of 2.0 with 80% power, keeping in mind that matching improves power, albeit by an unknown mechanism.
Statistical Methods
Patient characteristics were described according to their case/ control status. Association was measured using odds ratios (and 95% CI) through conditional logistic regression to take into account matching. Multivariate conditional logistic regression analysis was performed to further adjust for potential risk factors. As PSA measurement and number of prostate samples (biopsy or transurethral resection) were potentially in the causal pathway of prostate cancer, a sensitivity analysis without adjustment for those variables was also performed.
The association between prostate cancer and 5-ARI exposure was expected to be different whenever low or high grade cancer was considered. An interaction term between exposure and prostate cancer grade was introduced in the logistic model to allow different association strengths according to the considered individual outcome (low or high grade prostate cancer) and to test for homogeneity across these individual components of the composite outcome [23] . A sensitivity analysis was performed according to the recently proposed new five-tiered Gleason grade groups [24] .
Statistical analyses used the LOGISTIC procedure of the SAS software version 9.4 (SAS Institute Inc, Cary, NC, USA) with a STRATA statement.
Ethical Considerations
Regulatory approval was obtained for the study (CNIL: DR-2014-084; ClinicalTrials.gov identifier: NCT02873117). Overall rather than patient-level information about the study was allowed and was provided through the 'ARS Bretagne' website. Patients' informed consent was not required as all the data were de-identified.
Results
Patients
Among 74 596 eligible patients, 859 cases of confirmed prostate cancer were identified in 2012-2013 (Fig. 1) ; 767 cases (including 153 5-ARI users) were available for the analysis, matched to 3 835 controls (including 810 5-ARI users).
Descriptive Data
After matching, the mean patient age was 69.3 years, and patients with Gleason scores < 8 were younger than those 
Exposure Data
A total of 153 (20.0%) cases and 810 (21.1%) controls were 5-ARI users before the index date, and 400 patients had a duration of use of 5-ARI ≥ 2 years: 58 were cases (including 38 with Gleason score <8 and 20 with Gleason score ≥8) and 342 were controls (Table S3) . When comparing 5-ARI users with 5-ARI non-users, no substantial differences were observed, including in PSA measurement and prostate samples ( Table 2) . Most 5-ARI non-users received a-adrenoreceptor antagonists (tamsulosin, 35%; alfuzosin, 24%), but also Serenoas repens (22%) and Pygeum africanum (11%).
Main Results
Matched unadjusted estimates and confounder-adjusted estimates are shown in Fig. 2 (Table S4) .
Discussion
In the present study targeting patients receiving drugs licensed for symptomatic or complicated BPH, a qualitative significant heterogeneity was observed across cancer grades when estimating the association between prostate cancer and long-term 5-ARI use (≥ 2 years) vs no 5-ARI exposure.
The results of the present study differ in the important aspects of clinical setting and methodology from other observational studies [15] [16] [17] , but appear in line with the Prostate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial [4, 5] . Our clinical setting was more similar to the CombAT trial [14] than to the PCPT [4] and REDUCE trial [5] . In a Finnish cohort study, risk of cancer with scores 7-10 was nonsignificantly increased in finasteride users compared with non-users [15] . A Swedish population-based case-control study reported that an increasing duration of exposure to 5-ARI was associated with a decreased risk of Gleason scores 2-6 and 7; no significant association in risk of Gleason scores 8-10 was observed with increasing exposure time [16] . Lastly, another Swedish population-based cohort study [17] reported that 5-ARI use decreased the risk of prostate cancer with Gleason scores 6 and 7 and that 5-ARIs did not statistically significantly affect the long-term risk of prostate cancer with Gleason scores 8-10 over an 8-year period compared with not taking 5-ARIs. In that study, a statistically increased risk after <2 years of exposure to 5-ARI (hazard ratio 1.56) became not statistically significant (hazard ratio 1.25) with a further adjustment for PSA before treatment, and there was no increased risk thereafter. The authors explained that these early detected high grade cancers were probably potential prevalent cancers, more easily diagnosed after prostate shrinkage. Notably, a 1-year delay has been used to remove prevalent cancers detected by the initial PSA test [17] . Furthermore, a transient early increased risk of cancer could be related to a true effect of 5-ARI-selecting susceptible clones; previous studies showed no specific prostatic histological modification in finasteridetreated patients and suggested that high grade prostate cancer could be attributable to the cell capacity to survive in a perhaps less hormonally sensitive environment [25, 26] . These three observational studies used men free of prostate cancer as controls [16] , compared drug users with non-users [15] , or used non 5-ARI users as the reference [17] (no details of BPH status or non-5-ARI BPH treatment were provided). Interestingly, the studies by Murtola et al. [15] COPD, chronic obstructive pulmonary disease. *Before index date and the date of the sample which allowed the diagnosis of cancer for cases. † Number of prostate sample collection(s), i.e. biopsy or transurethral resection, before index date and the date of the sample which allowed the diagnosis of cancer for cases.
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© 2018 The Authors BJU International © 2018 BJU International and Robinson et al. [16] also assessed the association between exposure to a-adrenoreceptor antagonists and prostate cancer; men using a-adrenoreceptor antagonists had either an increased or a nonsignificant risk of low grade prostate cancer. This result was thought to be related to a detection bias considering that men with LUTS are more likely to be investigated for prostate cancer. Even in the PCPT, a detection bias was put forward to explain the observed higher proportion of high grade cancers in 5-ARI users; indeed, 5-ARIs decreased prostate volume but did not induce tumour shrinkage improving then biopsy detection. The last reassuring factor is that a higher mortality rate was not observed among long-term 5-ARI users [27] . The present study design did not allow the assessment of overall survival. Regardless, a diagnosis of high grade prostate cancer is associated with stress and the need for treatment despite the drug being initially given for a benign disease.
The present study has several strengths. First, we used a population-based nested matched case-control design which minimizes selection bias [28] . The selection of eligible patients for cohort entry was made through drug claims, which were collected in a timely manner and prospectively, thereby avoiding recall bias and minimizing misclassification of exposure or at least rendering it nondifferential. Second, when comparing treated patients, we selected patients seeking medical attention for symptoms justifying a drug prescription. This minimized confounding by indication compared with previous studies which used non-treated patients [4, 5, [15] [16] [17] as reference. Third, detection bias was minimized. As PSA measurement and prostate sampling are potentially in the causal pathway of prostate cancer, even though no PSA results were available, the recurrence of PSA measurement and the use of prostate sampling were proxies of prostate cancer exploration; therefore, we conducted a sensitivity analysis without adjustment for those variables, showing similar results to the main analysis with full adjustment. Fourth, we set up a 2-year restriction period during which patients had to remain free of prostate cancer diagnosis to be eligible for inclusion, reassuring us that cases were truly incident prostate cancer cases. Fifth, there was no attrition bias.
The study also has some limitations. The representativeness of the patient population is more debatable than it would be for a nationwide study, but linkage to pathology laboratories imposed a restricted area. We had no information on prostate volume and body mass index, but a previous study showed that such adjustments did not materially affect the results [15] . Other studies have suggested that prostate volume was not related to prostate cancer risk [29] and could not be predictive of histological grade [30] . We did not have 2 Conditional adjusted odds ratios for prostate cancer. Matching according to age and delay between the first observed delivery of drug for BPH and index date through an incidence density sampling design, with further adjustment for diabetes, lipid-lowering drug claims, obesity, chronic obstructive pulmonary disease, annual number of prostate sample collection(s) (i.e. biopsy or transurethral resection) before the sample which allowed the diagnosis of cancer for cases) and annual number of PSA measurements. P value for heterogeneity across cancer grades (high and low grade) when estimating association between prostate cancer and long-term (≥ 2 years) 5a-reductase (5-ARI) use vs no 5-ARI exposure (reference) = 0.005.
© 2018 The Authors BJU International © 2018 BJU International 297 information on dietary patterns, but when comparing drug users between each other such a healthy-user effect is thought to be less problematic. We had no valid information on family cancer status or on highest level of education attained, but such an adjustment did not seem to change the results in a previous study [16] . Lastly, there is a potential for exposure misclassification with regard to short-or mid-term users (<2 years) because we had no claims data before 2010; however, we are confident in our long-term user (≥ 2 years) classification whenever observed.
The rather reassuring message to date with regard to high grade prostate cancer should be switched to a more cautious message. Notwithstanding the clear clinical benefits of 5-ARIs, we should consider any substantial increased risk of high grade cancer (worse prognosis) when choosing between therapies for symptomatic or complicated BPH. Patients treated for > 2 years with 5-ARIs should be informed of the increased risk of the development of high grade disease.
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